Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis

International Journal of Molecular Sciences

Volumn 14, Issue 10, 2013, Pages 19867-19890

  Vonghia, Luisa ^a,b   Michielsen, Peter ^a   Francque, Sven ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Adaptive immunity; Adipokines; Innate immunity; Non alcoholic steatohepatitis (NASH)

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHEMOKINE RECEPTOR CCR2; DT 56A; GAMMA INTERFERON; GELATINASE A; GHRELIN; I KAPPA B KINASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 6 RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY CD3; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NATURAL PRODUCT; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE C; SONIC HEDGEHOG PROTEIN; SORAFENIB; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; ANTIGEN SPECIFICITY; B LYMPHOCYTE; BASOPHIL; CELL DIFFERENTIATION; CELL INTERACTION; CELL TRANSPLANTATION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; EOSINOPHIL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; KUPFFER CELL; LIPID METABOLISM; LIPID OXIDATION; LIPID PEROXIDATION; LIPID STORAGE; LIPOGENESIS; LIVER; LYMPHOCYTE ACTIVATION; MACROPHAGE; MAST CELL; METABOLIC REGULATION; NATURAL KILLER T CELL; NEUTROPHIL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; ANIMALS; FATTY LIVER; HUMANS; IMMUNITY, INNATE;

EID: 84885112550     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141019867     Document Type: Review

References (121)

1. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association. Hepatology 2012, 55, 2005-2023.
2. Blachier, M.; Leleu, H.; Peck-Radosavljevic, M.; Valla, D.C.; Roudot-Thoraval, F. The burden of liver disease in europe: A review of available epidemiological data. J. Hepatol. 2013, 58, 593-608.
3. Farrell, G.C.; Larter, C.Z. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006, 43, S99-S112.
4. Szczepaniak, L.S.; Nurenberg, P.; Leonard, D.; Browning, J.D.; Reingold, J.S.; Grundy, S.; Hobbs, H.H.; Dobbins, R.L. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 2005, 288, E462-E468.
5. Browning, J.D.; Szczepaniak, L.S.; Dobbins, R.; Nuremberg, P.; Horton, J.D.; Cohen, J.C.; Grundy, S.M.; Hobbs, H.H. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004, 40, 1387-1395.
6. Williams, C.D.; Stengel, J.; Asike, M.I.; Torres, D.M.; Shaw, J.; Contreras, M.; Landt, C.L.; Harrison, S.A. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 2011, 140, 124-131.
7. Chitturi, S.; Wong, V.W.; Farrell, G. Nonalcoholic fatty liver in asia: Firmly entrenched and rapidly gaining ground. J. Gastroenterol. Hepatol. 2011, 26 (Suppl 1), 163-172.
8. Okanoue, T.; Umemura, A.; Yasui, K.; Itoh, Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in japan. J. Gastroenterol. Hepatol. 2011, 26 (Suppl 1), 153-162.
9. Yasui, K.; Hashimoto, E.; Komorizono, Y.; Koike, K.; Arii, S.; Imai, Y.; Shima, T.; Kanbara, Y.; Saibara, T.; Mori, T.; et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2011, 9, 428-433.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 2001, 285, 2486-2497.
11. Tsochatzis, E.A.; Manolakopoulos, S.; Papatheodoridis, G.V.; Archimandritis, A.J. Insulin resistance and metabolic syndrome in chronic liver diseases: Old entities with new implications. Scand. J. Gastroenterol. 2009, 44, 6-14.
12. Schenk, S.; Saberi, M.; Olefsky, J.M. Insulin sensitivity: Modulation by nutrients and inflammation. J. Clin. Investig. 2008, 118, 2992-3002.
13. Asrih, M.; Jornayvaz, F.R. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J. Endocrinol. 2013, 218, R25-R36.
14. Day, C.P.; James, O.F. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998, 114, 842-845.
15. Tilg, H.; Moschen, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010, 52, 1836-1846.
16. Racanelli, V.; Rehermann, B. The liver as an immunological organ. Hepatology 2006, 43, S54-S62.
17. Parker, G.A.; Picut, C.A. Liver immunobiology. Toxicol. Pathol. 2005, 33, 52-62.
18. Thomson, A.W.; Knolle, P.A. Antigen-presenting cell function in the tolerogenic liver environment. Nat. Rev. Immunol. 2010, 10, 753-766.
19. Montalvo-Jave, E.E.; Escalante-Tattersfield, T.; Ortega-Salgado, J.A.; Pina, E.; Geller, D.A. Factors in the pathophysiology of the liver ischemia-reperfusion injury. J. Surg. Res. 2008, 147, 153-159.
20. Tosello-Trampont, A.C.; Landes, S.G.; Nguyen, V.; Novobrantseva, T.I.; Hahn, Y.S. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J. Biol. Chem. 2012, 287, 40161-40172.
21. Stienstra, R.; Saudale, F.; Duval, C.; Keshtkar, S.; Groener, J.E.; van Rooijen, N.; Staels, B.; Kersten, S.; Muller, M. Kupffer cells promote hepatic steatosis via interleukin-1β-dependent suppression of peroxisome proliferator-activated receptor α activity. Hepatology 2010, 51, 511-522.
22. De Vito, R.; Alisi, A.; Masotti, A.; Ceccarelli, S.; Panera, N.; Citti, A.; Salata, M.; Valenti, L.; Feldstein, A.E.; Nobili, V. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int. J. Mol. Med. 2012, 30, 49-56.
23. Miura, K.; Kodama, Y.; Inokuchi, S.; Schnabl, B.; Aoyama, T.; Ohnishi, H.; Olefsky, J.M.; Brenner, D.A.; Seki, E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology 2010, 139, 323-334.
24. Maher, J.J.; Leon, P.; Ryan, J.C. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology 2008, 48, 670-678.
25. Gao, B. Innate immunity and steatohepatitis: A critical role of another toll (tlr-9). Gastroenterology 2010, 139, 27-30.
26. Rivera, C.A.; Adegboyega, P.; van Rooijen, N.; Tagalicud, A.; Allman, M.; Wallace, M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007, 47, 571-579.
27. Bertola, A.; Bonnafous, S.; Anty, R.; Patouraux, S.; Saint-Paul, M.C.; Iannelli, A.; Gugenheim, J.; Barr, J.; Mato, J.M.; Marchand-Brustel, Y.; et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and nash in morbidly obese patients. PloS One 2010, 5, e13577.
28. Szabo, G.; Velayudham, A.; Romics, L., Jr.; Mandrekar, P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: The role of toll-like receptors 2 and 4. Alcohol. Clin. Exp. Res. 2005, 29, 140S-145S.
29. Wang, H.; Lafdil, F.; Kong, X.; Gao, B. Signal transducer and activator of transcription 3 in liver diseases: A novel therapeutic target. Int. J. Biol. Sci. 2011, 7, 536-550.
30. Tran, A.; Gual, P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin. Res. Hepatol. Gastroenterol. 2013, 37, 17-29.
31. Lynch, L.; Nowak, M.; Varghese, B.; Clark, J.; Hogan, A.E.; Toxavidis, V.; Balk, S.P.; O'Shea, D.; O'Farrelly, C.; Exley, M.A. Adipose tissue invariant nkt cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 2012, 37, 574-587.
32. Lumeng, C.N.; Bodzin, J.L.; Saltiel, A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Investig. 2007, 117, 175-184.
33. Vats, D.; Mukundan, L.; Odegaard, J.I.; Zhang, L.; Smith, K.L.; Morel, C.R.; Wagner, R.A.; Greaves, D.R.; Murray, P.J.; Chawla, A. Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. Cell Metab. 2006, 4, 13-24.
34. Bronte, V.; Zanovello, P. Regulation of immune responses by l-arginine metabolism. Nat. Rev. Immunol. 2005, 5, 641-654.
35. Kim, H.J.; Higashimori, T.; Park, S.Y.; Choi, H.; Dong, J.; Kim, Y.J.; Noh, H.L.; Cho, Y.R.; Cline, G.; Kim, Y.B.; et al. Differential effects of interleukin-6 and-10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004, 53, 1060-1067.
36. Fujisaka, S.; Usui, I.; Bukhari, A.; Ikutani, M.; Oya, T.; Kanatani, Y.; Tsuneyama, K.; Nagai, Y.; Takatsu, K.; Urakaze, M.; et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 2009, 58, 2574-2582.
37. Lumeng, C.N.; DelProposto, J.B.; Westcott, D.J.; Saltiel, A.R. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008, 57, 3239-3246.
38. Montes, V.N.; Turner, M.S.; Subramanian, S.; Ding, Y.; Hayden-Ledbetter, M.; Slater, S.; Goodspeed, L.; Wang, S.; Omer, M.; Den Hartigh, L.J.; et al. T cell activation inhibitors reduce CD8+ T cell and pro-inflammatory macrophage accumulation in adipose tissue of obese mice. PLoS One 2013, 8, e67709.
39. Bertola, A.; Deveaux, V.; Bonnafous, S.; Rousseau, D.; Anty, R.; Wakkach, A.; Dahman, M.; Tordjman, J.; Clement, K.; McQuaid, S.E.; et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 2009, 58, 125-133.
40. Nguyen, M.T.; Favelyukis, S.; Nguyen, A.K.; Reichart, D.; Scott, P.A.; Jenn, A.; Liu-Bryan, R.; Glass, C.K.; Neels, J.G.; Olefsky, J.M. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via toll-like receptors 2 and 4 and jnk-dependent pathways. J. Biol. Chem. 2007, 282, 35279-35292.
41. Diao, H.; Kon, S.; Iwabuchi, K.; Kimura, C.; Morimoto, J.; Ito, D.; Segawa, T.; Maeda, M.; Hamuro, J.; Nakayama, T.; et al. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004, 21, 539-550.
42. Syn, W.K.; Choi, S.S.; Liaskou, E.; Karaca, G.F.; Agboola, K.M.; Oo, Y.H.; Mi, Z.; Pereira, T.A.; Zdanowicz, M.; Malladi, P.; et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011, 53, 106-115.
43. Syn, W.K.; Witek, R.P.; Curbishley, S.M.; Jung, Y.; Choi, S.S.; Enrich, B.; Omenetti, A.; Agboola, K.M.; Fearing, C.M.; Tilg, H.; et al. Role for hedgehog pathway in regulating growth and function of invariant NKT cells. Eur. J. Immunol. 2009, 39, 1879-1892.
44. Tajiri, K.; Shimizu, Y.; Tsuneyama, K.; Sugiyama, T., Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2009, 21, 673-680.
45. Guebre-Xabier, M.; Yang, S.; Lin, H.Z.; Schwenk, R.; Krzych, U.; Diehl, A.M. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: Potential mechanism for sensitization to liver damage. Hepatology 2000, 31, 633-640.
46. Li, Z.; Soloski, M.J.; Diehl, A.M. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005, 42, 880-885.
47. Adler, M.; Taylor, S.; Okebugwu, K.; Yee, H.; Fielding, C.; Fielding, G.; Poles, M. Intrahepatic natural killer T cell populations are increased in human hepatic steatosis. World J. Gastroenterol. 2011, 17, 1725-1731.
48. Syn, W.K.; Oo, Y.H.; Pereira, T.A.; Karaca, G.F.; Jung, Y.; Omenetti, A.; Witek, R.P.; Choi, S.S.; Guy, C.D.; Fearing, C.M.; et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010, 51, 1998-2007.
49. Syn, W.K.; Agboola, K.M.; Swiderska, M.; Michelotti, G.A.; Liaskou, E.; Pang, H.; Xie, G.; Philips, G.; Chan, I.S.; Karaca, G.F.; et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 2012, 61, 1323-1329.
50. Lynch, L.; O'Shea, D.; Winter, D.C.; Geoghegan, J.; Doherty, D.G.; O'Farrelly, C. Invariant nkt cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur. J. Immunol. 2009, 39, 1893-1901.
51. Elgazar-Carmon, V.; Rudich, A.; Hadad, N.; Levy, R., Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J. Lipid Res. 2008, 49, 1894-1903.
52. Talukdar, S.; Oh da, Y.; Bandyopadhyay, G.; Li, D.; Xu, J.; McNelis, J.; Lu, M.; Li, P.; Yan, Q.; Zhu, Y.; et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat. Med. 2012, 18, 1407-1412.
53. Rensen, S.S.; Slaats, Y.; Nijhuis, J.; Jans, A.; Bieghs, V.; Driessen, A.; Malle, E.; Greve, J.W.; Buurman, W.A. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am. J. Pathol. 2009, 175, 1473-1482.
54. Rensen, S.S.; Bieghs, V.; Xanthoulea, S.; Arfianti, E.; Bakker, J.A.; Shiri-Sverdlov, R.; Hofker, M.H.; Greve, J.W.; Buurman, W.A. Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. PLoS One 2012, 7, e52411.
55. Wu, D.; Molofsky, A.B.; Liang, H.E.; Ricardo-Gonzalez, R.R.; Jouihan, H.A.; Bando, J.K.; Chawla, A.; Locksley, R.M. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011, 332, 243-247.
56. Suzukawa, M.; Nagase, H.; Ogahara, I.; Han, K.; Tashimo, H.; Shibui, A.; Koketsu, R.; Nakae, S.; Yamaguchi, M.; Ohta, K. Leptin enhances survival and induces migration, degranulation, and cytokine synthesis of human basophils. J. Immunol. 2011, 186, 5254-5260.
57. Liu, J.; Divoux, A.; Sun, J.; Zhang, J.; Clement, K.; Glickman, J.N.; Sukhova, G.K.; Wolters, P.J.; Du, J.; Gorgun, C.Z.; et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat. Med. 2009, 15, 940-945.
58. Divoux, A.; Moutel, S.; Poitou, C.; Lacasa, D.; Veyrie, N.; Aissat, A.; Arock, M.; Guerre-Millo, M.; Clement, K. Mast cells in human adipose tissue: Link with morbid obesity, inflammatory status, and diabetes. J. Clin. Endocrinol. Metab. 2012, 97, E1677-E1685.
59. Altintas, M.M.; Nayer, B.; Walford, E.C.; Johnson, K.B.; Gaidosh, G.; Reiser, J.; de La Cruz-Munoz, N.; Ortega, L.M.; Nayer, A. Leptin deficiency-induced obesity affects the density of mast cells in abdominal fat depots and lymph nodes in mice. Lipids Health Dis. 2012, 11, doi:10.1186/1476-511X-11-21.
60. Jin, Y.L.; Zhou, Q.; Tian, C.; Liu, H.G.; Hayashi, Y.; Enzan, H. Effects of mast cells on degradation of collagen fibers in dimethylnitrosamine-induced hepatic fibrosis of rat. Chin. J. Pathol. 2012, 41, 260-264.
61. Connolly, M.K.; Bedrosian, A.S.; Mallen-St Clair, J.; Mitchell, A.P.; Ibrahim, J.; Stroud, A.; Pachter, H.L.; Bar-Sagi, D.; Frey, A.B.; Miller, G. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-α. J. Clin. Investig. 2009, 119, 3213-3225.
62. Jiao, J.; Sastre, D.; Fiel, M.I.; Lee, U.E.; Ghiassi-Nejad, Z.; Ginhoux, F.; Vivier, E.; Friedman, S.L.; Merad, M.; Aloman, C. Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology 2012, 55, 244-255.
63. Henning, J.R.; Graffeo, C.S.; Rehman, A.; Fallon, N.C.; Zambirinis, C.P.; Ochi, A.; Barilla, R.; Jamal, M.; Deutsch, M.; Greco, S.; et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology 2013, 58, 589-602.
64. Bertola, A.; Ciucci, T.; Rousseau, D.; Bourlier, V.; Duffaut, C.; Bonnafous, S.; Blin-Wakkach, C.; Anty, R.; Iannelli, A.; Gugenheim, J.; et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes 2012, 61, 2238-2247.
65. Wu, H.; Ghosh, S.; Perrard, X.D.; Feng, L.; Garcia, G.E.; Perrard, J.L.; Sweeney, J.F.; Peterson, L.E.; Chan, L.; Smith, C.W.; et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007, 115, 1029-1038.
66. Cipolletta, D.; Kolodin, D.; Benoist, C.; Mathis, D. Tissular Tregs: A unique population of adipose-tissue-resident FOXP3+CD4+ T cells that impacts organismal metabolism. Semin. Immunol. 2011, 23, 431-437.
67. Winer, S.; Chan, Y.; Paltser, G.; Truong, D.; Tsui, H.; Bahrami, J.; Dorfman, R.; Wang, Y.; Zielenski, J.; Mastronardi, F.; et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 2009, 15, 921-929.
68. Pacifico, L.; di Renzo, L.; Anania, C.; Osborn, J.F.; Ippoliti, F.; Schiavo, E.; Chiesa, C. Increased T-helper interferon-γ-secreting cells in obese children. Eur. J. Endocrinol. 2006, 154, 691-697.
69. Rocha, V.Z.; Folco, E.J.; Sukhova, G.; Shimizu, K.; Gotsman, I.; Vernon, A.H.; Libby, P. Interferon-γ, a Th1 cytokine, regulates fat inflammation: A role for adaptive immunity in obesity. Circ. Res. 2008, 103, 467-476.
70. Kintscher, U.; Hartge, M.; Hess, K.; Foryst-Ludwig, A.; Clemenz, M.; Wabitsch, M.; Fischer-Posovszky, P.; Barth, T.F.; Dragun, D.; Skurk, T.; et al. T-lymphocyte infiltration in visceral adipose tissue: A primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscl. Thromb. Vasc. Biol. 2008, 28, 1304-1310.
71. Nishimura, S.; Manabe, I.; Nagasaki, M.; Eto, K.; Yamashita, H.; Ohsugi, M.; Otsu, M.; Hara, K.; Ueki, K.; Sugiura, S.; et al. CD8+ effector t cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 2009, 15, 914-920.
72. Kaminski, D.A.; Randall, T.D. Adaptive immunity and adipose tissue biology. Trends Immunol. 2010, 31, 384-390.
73. Barbi, J.; Pardoll, D.; Pan, F. Metabolic control of the Treg/Th17 axis. Immunol. Rev. 2013, 252, 52-77.
74. Oo, Y.H.; Hubscher, S.G.; Adams, D.H. Autoimmune hepatitis: New paradigms in the pathogenesis, diagnosis, and management. Hepatol. Int. 2010, 4, 475-493.
75. Ma, X.; Hua, J.; Mohamood, A.R.; Hamad, A.R.; Ravi, R.; Li, Z. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 2007, 46, 1519-1529.
76. Soderberg, C.; Marmur, J.; Eckes, K.; Glaumann, H.; Sallberg, M.; Frelin, L.; Rosenberg, P.; Stal, P.; Hultcrantz, R. Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis. Acta Pathol. Microbiol. Immunol. Scand. 2011, 119, 412-420.
77. Feuerer, M.; Herrero, L.; Cipolletta, D.; Naaz, A.; Wong, J.; Nayer, A.; Lee, J.; Goldfine, A.B.; Benoist, C.; Shoelson, S.; et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009, 15, 930-939.
78. De Rosa, V.; Procaccini, C.; Cali, G.; Pirozzi, G.; Fontana, S.; Zappacosta, S.; La Cava, A.; Matarese, G. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007, 26, 241-255.
79. Bosello, O.; Zamboni, M. Visceral obesity and metabolic syndrome. Obes. Rev. 2000, 1, 47-56.
80. Cipolletta, D.; Feuerer, M.; Li, A.; Kamei, N.; Lee, J.; Shoelson, S.E.; Benoist, C.; Mathis, D. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012, 486, 549-553.
81. Eller, K.; Kirsch, A.; Wolf, A.M.; Sopper, S.; Tagwerker, A.; Stanzl, U.; Wolf, D.; Patsch, W.; Rosenkranz, A.R.; Eller, P. Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes 2011, 60, 2954-2962.
82. Zeng, C.; Shi, X.; Zhang, B.; Liu, H.; Zhang, L.; Ding, W.; Zhao, Y. The imbalance of Th17/Th1/tregs in patients with type 2 diabetes: Relationship with metabolic factors and complications. J. Mol. Med. 2012, 90, 175-186.
83. Ryba-Stanislawowska, M.; Skrzypkowska, M.; Mysliwska, J.; Mysliwiec, M., The serum IL-6 profile and Treg/Th17 peripheral cell populations in patients with type 1 diabetes. Mediat. Inflamm. 2013, 2013, doi:10.1155/2013/205284.
84. Zhao, L.; Qiu de, K.; Ma, X. Th17 cells: The emerging reciprocal partner of regulatory T cells in the liver. J. Dig. Dis. 2010, 11, 126-133.
85. Abdulahad, W.H.; Boots, A.M.; Kallenberg, C.G. FOXP3+ CD4+ T cells in systemic autoimmune diseases: The delicate balance between true regulatory T cells and effector Th-17 cells. Rheumatology 2011, 50, 646-656.
86. Tang, Y.; Bian, Z.; Zhao, L.; Liu, Y.; Liang, S.; Wang, Q.; Han, X.; Peng, Y.; Chen, X.; Shen, L.; et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin. Exp. Immunol. 2011, 166, 281-290.
87. Sumarac-Dumanovic, M.; Stevanovic, D.; Ljubic, A.; Jorga, J.; Simic, M.; Stamenkovic-Pejkovic, D.; Starcevic, V.; Trajkovic, V.; Micic, D., Increased activity of interleukin-23/interleukin-17 pro-inflammatory axis in obese women. Int. J. Obes. 2009, 33, 151-156.
88. Yu, Y.; Liu, Y.; Shi, F.D.; Zou, H.; Matarese, G.; La Cava, A. Cutting edge: Leptin-induced rorgammat expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. J. Immunol. 2013, 190, 3054-3058.
89. Zuniga, L.A.; Shen, W.J.; Joyce-Shaikh, B.; Pyatnova, E.A.; Richards, A.G.; Thom, C.; Andrade, S.M.; Cua, D.J.; Kraemer, F.B.; Butcher, E.C. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J. Immunol. 2010, 185, 6947-6959.
90. Meng, F.; Wang, K.; Aoyama, T.; Grivennikov, S.I.; Paik, Y.; Scholten, D.; Cong, M.; Iwaisako, K.; Liu, X.; Zhang, M.; et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012, 143, 765-776.
91. Winer, S.; Paltser, G.; Chan, Y.; Tsui, H.; Engleman, E.; Winer, D.; Dosch, H.M. Obesity predisposes to Th17 bias. Eur. J. Immunol. 2009, 39, 2629-2635.
92. Winer, D.A.; Winer, S.; Shen, L.; Wadia, P.P.; Yantha, J.; Paltser, G.; Tsui, H.; Wu, P.; Davidson, M.G.; Alonso, M.N.; et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 2011, 17, 610-617.
93. Kawasaki, K.; Abe, M.; Tada, F.; Tokumoto, Y.; Chen, S.; Miyake, T.; Furukawa, S.; Matsuura, B.; Hiasa, Y.; Onji, M. Blockade of B-cell-activating factor signaling enhances hepatic steatosis induced by a high-fat diet and improves insulin sensitivity. Lab. Investig. 2013, 93, 311-321.
94. Mauri, C.; Ehrenstein, M.R., The "short" history of regulatory B cells. Trends Immunol. 2008, 29, 34-40.
95. Eliakim, A.; Schwindt, C.; Zaldivar, F.; Casali, P.; Cooper, D.M. Reduced tetanus antibody titers in overweight children. Autoimmunity 2006, 39, 137-141.
96. Roberts, D.W.; Wolff, G.L.; Campbell, W.L. Differential effects of the mottled yellow and pseudoagouti phenotypes on immunocompetence in Avy/a mice. Proc. Natl. Acad. Sci. USA 1984, 81, 2152-2156.
97. Tsochatzis, E.A.; Papatheodoridis, G.V.; Archimandritis, A.J. Adipokines in nonalcoholic steatohepatitis: From pathogenesis to implications in diagnosis and therapy. Mediat. Inflamm. 2009, 2009, doi:10.1155/2009/831670.
98. Gonciarz, M.; Bielanski, W.; Partyka, R.; Brzozowski, T.; Konturek, P.C.; Eszyk, J.; Celinski, K.; Reiter, R.J.; Konturek, S.J. Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin. J. Pineal Res. 2013, 54, 154-161.
99. Kamada, Y.; Takehara, T.; Hayashi, N. Adipocytokines and liver disease. J. Gastroenterol. 2008, 43, 811-822.
100. Matsumoto, H.; Tamura, S.; Kamada, Y.; Kiso, S.; Fukushima, J.; Wada, A.; Maeda, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y.; et al. Adiponectin deficiency exacerbates lipopolysaccharide/D-galactosamine-induced liver injury in mice. World J. Gastroenterol. 2006, 12, 3352-3358.
101. Yokota, T.; Oritani, K.; Takahashi, I.; Ishikawa, J.; Matsuyama, A.; Ouchi, N.; Kihara, S.; Funahashi, T.; Tenner, A.J.; Tomiyama, Y.; et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96, 1723-1732.
102. Sun, B.; Karin, M. Obesity, inflammation, and liver cancer. J. Hepatol. 2012, 56, 704-713.
103. Polyzos, S.A.; Kountouras, J.; Zavos, C.; Deretzi, G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: A hypothesis based on critical review of the literature. J. Clin. Gastroenterol. 2011, 45, 50-54.
104. Testa, R.; Franceschini, R.; Giannini, E.; Cataldi, A.; Botta, F.; Fasoli, A.; Tenerelli, P.; Rolandi, E.; Barreca, T. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J. Hepatol. 2000, 33, 33-37.
105. Wang, Y.Y.; Lin, S.Y. Leptin in relation to hepatocellular carcinoma in patients with liver cirrhosis. Horm. Res. 2003, 60, 185-190.
106. Lord, G.M.; Matarese, G.; Howard, J.K.; Baker, R.J.; Bloom, S.R.; Lechler, R.I. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998, 394, 897-901.
107. Procaccini, C.; Jirillo, E.; Matarese, G. Leptin as an immunomodulator. Mol. Asp. Med. 2012, 33, 35-45.
108. Dhurandhar, N.V.; Kulkarni, P.R.; Ajinkya, S.M.; Sherikar, A.A.; Atkinson, R.L. Association of adenovirus infection with human obesity. Obes. Res. 1997, 5, 464-469.
109. Marchesini, G.; Pagotto, U.; Bugianesi, E.; de Iasio, R.; Manini, R.; Vanni, E.; Pasquali, R.; Melchionda, N.; Rizzetto, M. Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. J. Clin. Endocrinol. Metab. 2003, 88, 5674-5679.
110. Pagano, C.; Soardo, G.; Pilon, C.; Milocco, C.; Basan, L.; Milan, G.; Donnini, D.; Faggian, D.; Mussap, M.; Plebani, M.; et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J. Clin. Endocrinol. Metab. 2006, 91, 1081-1086.
111. Bo, S.; Ciccone, G.; Durazzo, M.; Gambino, R.; Massarenti, P.; Baldi, I.; Lezo, A.; Tiozzo, E.; Pauletto, D.; Cassader, M.; et al. Efficacy of antioxidant treatment in reducing resistin serum levels: A randomized study. PLoS Clin. Trials 2007, 2, e17.
112. El-Assal, O.; Hong, F.; Kim, W.H.; Radaeva, S.; Gao, B. IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell. Mol. Immunol. 2004, 1, 205-211.
113. Von Boehmer, H.; Daniel, C. Therapeutic opportunities for manipulating T reg cells in autoimmunity and cancer. Nat. Rev. Drug Discov. 2013, 12, 51-63.
114. Ilan, Y.; Maron, R.; Tukpah, A.M.; Maioli, T.U.; Murugaiyan, G.; Yang, K.; Wu, H.Y.; Weiner, H.L. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc. Natl. Acad. Sci. USA 2010, 107, 9765-9770.
115. Da Cunha, A.P.; Weiner, H.L. Induction of immunological tolerance by oral anti-CD3. Clin. Dev. Immunol. 2012, 2012, doi:10.1155/2012/425021.
116. NasVax. Nasvax Announces the Success Of A Phase 2a Clinical Trial Of A New Oral Immunotherapy For Fatty Liver Disease. Available online: http://www.businesswire.com/news/ home/20110321005934/en/NasVax-Announces-Success-Phase-2a-Clinical-Trial (accessed on 7 August 2013).
117. Adar, T.; Ben Ya'acov, A.; Lalazar, G.; Lichtenstein, Y.; Nahman, D.; Mizrahi, M.; Wong, V.; Muller, B.; Rawlin, G.; Ilan, Y. Oral administration of immunoglobulin g-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. Clin. Exp. Immunol. 2012, 167, 252-260.
118. Mizrahi, M.; Shabat, Y.; Ben Ya'acov, A.; Lalazar, G.; Adar, T.; Wong, V.; Muller, B.; Rawlin, G.; Ilan, Y. Alleviation of insulin resistance and liver damage by oral administration of imm124-E is mediated by increased tregs and associated with increased serum GLP-1 and adiponectin: Results of a phase I/II clinical trial in NASH. J. Inflamm. Res. 2012, 5, 141-150.
119. Shabat, Y.; Lichtenstein, Y.; Zolotarov, L.; Ben Ya'acov, A.; Ilan, Y. Hepatoprotective effect of dt56a is associated with changes in natural killer t cells and regulatory t cells. J. Dig. Dis. 2013, 14, 84-92.
120. TGFTX1 Program: Successful Identification Of Proprietary Rorgt Ligands For The Treatment of Auto-Immune Diseas. Available online: http://genfit.com/en/media/press-room/ index.html?tx_ttnews[tt_news]=2613&tx_ttnews[backPid]=240&cHash=b5f3afe981 (accessed on 7 August 2013).
121. Deng, Y.R.; Ma, H.D.; Tsuneyama, K.; Yang, W.; Wang, Y.H.; Lu, F.T.; Liu, C.H.; Liu, P.; He, X.S.; Diehl, A.M.; et al. Stat3-mediated attenuation of ccl-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. J. Autoimmun. 2013, doi:10.1016/j.jaut.2013.07.008.